Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study.

Authors

M. Joerger

The Netherlands Cancer Institute, Amsterdam, Netherlands

M. Joerger , S. A. Burgers , P. Baas , E. F. Smit , T. J. Haitjema , M. P. L. Bard , V. D. Doodeman , P. H. M. Smits , A. Vincent , A. Huitema , J. H. Beijnen , J. H. M. Schellens

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic non-squamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05.

First Author: F. Zappa

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.

First Author: Helena Alexandra Yu

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).

First Author: Guru P. Sonpavde

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) + platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian.

First Author: Luis G. Paz-Ares